HRT risks and benefits: what changed in 2026

For years, estrogen products for menopause carried a boxed warning about heart disease, stroke, breast cancer and probable dementia, based on the Women’s Health Initiative (WHI) trials. In November 2025 the FDA said it would remove most of that warning, and in February 2026 it approved the first shorter labels. The change is real, but it is rolling out product by product, and it did not remove every risk.

Here is what changed, what the labels said when we checked on October 18, 2026, and what the trial data show in numbers you can weigh.

What the FDA changed

On Nov 10, 2025, the FDA announced it was working with companies to remove references to cardiovascular disease, breast cancer and probable dementia from the boxed warnings on menopausal hormone therapy. It said it was not seeking to remove the boxed warning for endometrial cancer on systemic estrogen-alone products. It also said labels would recommend starting systemic hormone therapy within 10 years of menopause onset or before age 60, with timing and duration left to you and your prescriber.

On Feb 12, 2026, the FDA approved the first revised labels: six products, one from each of four groups (systemic combination therapy, systemic estrogen alone, systemic progestogen alone and topical vaginal estrogen). It said 29 drug companies had submitted proposed changes.

What the labels say today

Each product’s label changes only when its maker’s revision is approved, so the wording you see depends on the product. This is what we read on DailyMed on October 18, 2026:

So if your patch or pill insert still shows the long boxed warning, that reflects the label you were given, not a different risk from a newer product. The Divigel label now says, in its dosing section, to consider starting in women under 60 or within 10 years of menopause onset.

The benefits

The North American Menopause Society’s 2022 position statement says hormone therapy remains the most effective treatment for hot flashes and night sweats and for the genitourinary syndrome of menopause (vaginal dryness, irritation and urinary symptoms), and that it prevents bone loss and fracture. For women under 60 or within 10 years of menopause onset with no contraindications, it calls the benefit-risk ratio favorable for bothersome hot flashes and for preventing bone loss.

The size of the hot flash benefit shows up in the label trials. In a Climara study, weekly hot flushes fell from 46 to 20 (67%) on the 0.05 mg patch and from 52 to 16 (72%) on the 0.1 mg patch, compared with an 18% drop on placebo.

The fracture benefit appears in the WHI. In the estrogen-plus-progestin trial, hip fractures ran at 11 per 10,000 women a year on hormones against 16 on placebo, and total fractures at 152 against 199.

The risks in numbers

The WHI numbers come from women whose average age was 63, taking oral conjugated estrogens. That is part of why the FDA and the menopause society now separate them from women starting treatment earlier. The figures below are from the WHI tables printed on the Climara and Divigel labels, as events per 10,000 women per year.

Estrogen plus progestin (women with a uterus)

That trial, of 16,608 women, was stopped early after an average of 5.6 years. It used conjugated estrogens with medroxyprogesterone acetate, not estradiol with micronized progesterone.

Estrogen alone (women without a uterus)

In the estrogen-alone trial, stroke and leg clots were more common on estrogen (relative risks 1.35 and 1.48), while invasive breast cancer was less common (28 versus 35 per 10,000 women a year, not statistically significant) and hip fractures were fewer (13 versus 19).

The picture is different for younger women. Among women aged 50 to 59 in that trial, the label shows 17 coronary events per 10,000 women a year on estrogen against 28 on placebo, and 29 deaths against 40. Neither difference was statistically significant, but neither points toward harm.

Probable dementia

The dementia warning came from the WHI Memory Study, which enrolled women 65 and older. Probable dementia ran at 45 versus 22 cases per 10,000 women a year on estrogen plus progestin, and 37 versus 25 on estrogen alone. The label notes it is unknown whether this applies to younger women.

What stays the same

Estrogen alone and the uterus

Estrogen alone raises the risk of endometrial cancer if you still have a uterus. That warning stays boxed on systemic estrogen. Adding a progestogen protects the lining: on the Prometrium label, endometrial hyperplasia occurred in 6% of women taking progesterone 200 mg for 12 days a cycle with estrogen over three years, against 64% on estrogen alone. See progesterone.

Who should not take it

The estradiol labels still list these contraindications: unexplained vaginal bleeding, breast cancer now or in the past, an estrogen-dependent cancer, a past or current blood clot, stroke or heart attack, liver disease, and clotting disorders such as protein C or S deficiency. The labels also say not to use estrogen to prevent heart disease or dementia.

Route and type matter

The menopause society says the risks differ by type, dose, duration, route, timing and whether a progestogen is used. The clearest example is blood clots. In a UK study published in the BMJ in 2019, comparing 80,396 women with blood clots with 391,494 controls, oral HRT was linked to a 58% higher risk (odds ratio 1.58), while estrogen through the skin was not linked to any increase (0.93). Oral estradiol carried a lower risk than oral conjugated equine estrogens. This was an observational study, so it shows associations, not cause and effect, and the FDA labels have not split their warnings by route. Our patch vs pill guide covers the practical differences.

Vaginal estrogen is a separate case. It is low-dose and local, and the menopause society recommends it for genitourinary symptoms in women who don’t need systemic therapy.

If you can’t or don’t want to take hormones

The menopause society’s 2023 nonhormone statement recommends cognitive behavioral therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin and fezolinetant for hot flashes, and says hormone therapy remains the most effective option. Two newer non-hormonal pills have their own warnings: Veozah carries a boxed warning for liver injury, and Lynkuet warns about sleepiness and liver enzymes. See our list of non-hormonal hot flash treatment.

The bottom line

The FDA now treats HRT’s heart, breast cancer and dementia warnings as overstated for most women who start before 60 or within 10 years of menopause, but as of October 18, 2026 many generic pill and patch labels still print the older boxed warning, and the endometrial cancer warning stays for estrogen taken alone. The trial numbers show real but modest absolute risks, a fracture benefit and the largest effect on hot flashes of any treatment. Weigh them with a licensed clinician who knows your history; our ranked list of menopause providers and the menopause hub show where to start.